Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacementRaniero Chimienti, Lorenzo Piemonti, Alessandro Cospito et al.|Cell Reports|2022Cited by 33
Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I−/− iPSC-derived β cells for cell therapy of type 1 diabetesRaniero Chimienti, Lorenzo Piemonti, Tania Baccega et al.|Cytotherapy|2020Cited by 2